Helus Pharma

Update in progress

HELP (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cybin Inc., doing business as Helus Pharma, is a clinical-stage neuropsychiatry company developing psychedelic-based therapeutics. Its programs include CYB003, a deuterated psilocybin analog in phase 3 for major depressive disorder; CYB004, a deuterated DMT in phase 2 for generalized anxiety disorder; SPL028 (deuterated DMT) completed phase 1; SPL026 for MDD; and CYB005, a preclinical phenethylamine derivative. Headquartered in Toronto, it also has a Segal Trials partnership for the PARADIGM program.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive